Improving Dermatologic Care for Patients with Skin of Color

Health care providers must improve their understanding and education regarding skin of color. Many established guidelines and treatments are based on research predominantly involving lighter skin tones, complicating effective diagnosis and management for darker-skinned populations. For instance, the Fitzpatrick skin phototype classification, which categorizes skin types based on UV reaction, was originally designed for Caucasian skin and has limitations in accurately representing darker skin types. Although types V and VI have been included, this system can mislead clinicians regarding burn risks in these skin types.

Clinicians should differentiate between constitutive pigmentation, which is genetically determined, and facultative pigmentation, which occurs due to environmental factors. Recognizing these distinctions is crucial for addressing conditions like post-inflammatory hyperpigmentation (PIH), which is more pronounced in patients with skin of color due to heightened pigmentation responses.

A significant concern is the lack of diversity in clinical trials, where approximately 75% of participants are White, with only 11% Hispanic, 8% African-American, and 6% Asian. This disparity limits understanding of treatment responses across varied skin tones and contributes to diagnostic delays and mismanagement in darker-skinned individuals.

As a result, patients may face complications, such as increased risks of PIH when their conditions are improperly addressed. Clinicians should carefully discuss the limited research surrounding medications' use in darker skin tones to ensure safe treatment recommendations. Enhancing educational resources and outreach efforts to include more diverse case studies is essential for improving care.

Conditions such as melasma, keloids, and acne may manifest differently in patients with skin of color. Among these, PIH is a prevalent concern, characterized by dark patches resulting from increased melanin production following inflammation or injury. The inflammatory response can trigger heightened melanocyte activity, increasing the likelihood of pigmentation changes.

To manage hyperpigmentation, treatments should target the underlying causes of inflammation. Options can vary depending on whether the discoloration is in the epidermal or dermal layers of the skin. Effective treatments include topical products like tretinoin or azelaic acid, oral medications such as tranexamic acid, and carefully applied laser therapies.

Patient education and counseling play critical roles in ensuring effective treatment outcomes. Clinicians must clarify how skin of color may react differently to treatments and the potential for increased inflammation. Emphasizing appropriate sun protection for all skin types is vital to prevent further complications.

Pharmacists also have a pivotal role in bridging the care gap for patients with skin of color by recommending suitable over-the-counter treatments and reinforcing the importance of adherence to therapy. Their accessibility makes them key players in addressing patients’ dermatologic needs, from counseling on medication use to managing the associated risks of treatments.

Awareness of how dermatologic conditions and medications impact individuals with diverse skin tones is crucial for equitable care delivery. It is essential for healthcare professionals to advocate for increased diversity in research and resources to improve dermatologic outcomes for patients with skin of color.